(Q44045676)

English

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

scientific article published in June 2002

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Baum

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

A U Budzar

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

J Cuzick

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

J Forbes

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

J H Houghton

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

J G M Klijn

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

T Sahmoud

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ATAC Trialists' Group

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

359

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

9324

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

2131-2139

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Endocrine treatment of breast cancer in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gynaecological monitoring during tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and risk of idiopathic venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen therapy for breast cancer and endometrial cancer risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and contralateral breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Future possibilities in the prevention of breast cancer: breast cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rheumatoid symptoms following breast cancer treatment: a controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Postchemotherapy rheumatism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Menopause, oestrogens and arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

How are bisphosphonates used today in breast cancer clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909088-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(02)09088-8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44045676&oldid=2105939040"